Senseonics Posts Record Revenue Growth as It Tightens Control Over European Operations — Senseonics Holdings, Inc.

Event summary

Senseonics reported $14.5 million in Q2 revenue, up ~120% YoY, driven by U.S. growth of over 150%.
Gross margin improved to 59%, prompting an upward revision of full-year guidance to 58–61%.
The company completed the transition of European commercial operations from Ascensia in June.
Senseonics raised $100 million in Q2, including a $90 million equity offering and expanded credit facility.

The big picture

Senseonics' aggressive push to bring European operations in-house reflects a broader trend among medtech firms seeking tighter control over commercialization. The company's ability to scale its U.S. success globally while maintaining margins will be critical as it competes with established continuous glucose monitoring players.

What we're watching

Execution Risk: Whether Senseonics can sustain its rapid U.S. growth while integrating European operations.
Margin Sustainability: The pace at which gross margins will hold up amid rising R&D and commercial integration costs.
Product Expansion: How the rollout of Eversense 365 with automated insulin delivery systems will impact adoption.